SGP

SpyGlass is a late-stage biopharma with no approved products and, by its own admission, 'no products approved for commercial sale' and 'no revenues from sales of any products.' The revenue line is blank in both FY2024 and FY2025, while the net loss widened 36.7% to -$39.9M and the operating loss deepened 53.2% to -$41.4M as R&D spend jumped 46% to $29.2M to fund two registrational Phase 3 trials initiated in July 2025. Operating cash burn is -$32.7M and accelerating (-48.5% YoY). The entire equity story rests on one candidate — the BIM-IOL System — with enrollment not complete until 2027, a 505(b)(2) NDA not planned until 2028, and thus no realistic approval or first revenue before ~2029. Per the filing, the company is 'substantially dependent on the success of our lead product candidate,' making this a textbook binary outcome.

The balance sheet looks superficially odd — stockholders' equity is -$98.8M and the liabilities/equity ratio of -0.10x is meaningless — but this is the normal pre-IPO artifact of redeemable convertible preferred stock sitting outside permanent equity; the accumulated deficit is -$105M. Liquidity is the one genuine bright spot: cash rose to $96.4M and the February 2026 IPO added $172.5M in gross proceeds (10,781,250 shares at $16.00). That funds the Phase 3 program for now, but running two ~400-patient trials across 45 sites against a growing burn means additional capital — and dilution — is likely before commercialization, a risk management flags explicitly ('we will need substantial additional capital... which may cause dilution to our stockholders').